Masimo, Staar Name New Leaders
Masimo and Staar Surgical appointed new executives amid prior deal and proxy turmoil. Masimo named Tim Benner president under Danaher ownership, succeeding Katie Szyman after Masimo’s $9.9B Danaher acquisition. Staar made Warren Foust permanent CEO after a failed $1.6B Alcon sale. Staar Q1 revenue rose to $93.5M; Q2 revenue expected over $90M.
How this was made
The 30-second read
Why it matters
For traders, the actionable elements are Staar’s preliminary Q2 revenue outlook and the Aug. 12 full-results date, plus Masimo’s FDA 510(k) clearance and leadership transition under Danaher.
Market read
This is a leadership-and-execution update with a concrete FDA clearance for Masimo and a near-term revenue guide plus earnings date for Staar.
What to watch
For Staar, the failed Alcon sale could leave lingering strategic uncertainty, and the Q2 guidance may be sensitive to distributor inventory normalization in China.
Background
The article frames both Masimo and Staar as emerging from turbulent periods involving proxy battles, acquisitions, and failed deals, with new executives taking the helm.
Ticker impact
Staar promoted Warren Foust to permanent CEO after the Alcon $1.6B sale fell through, and the company guided Q2 revenue to exceed $90M.
Potentially positive near-term reaction, especially into Aug. 12 full results, if investors view the guidance and China demand rebound as credible.
The article includes a clear, time-sensitive guidance datapoint (preliminary Q2 revenue >$90M, +120% YoY) and a defined upcoming catalyst (full results Aug. 12 after close).
Market effects
Signals ongoing consolidation and governance churn in medtech, while FDA clearances and product pipeline execution remain key differentiators for monitoring platforms and ophthalmic devices.
Orange County medtech names show continued investor focus on execution under new leadership and parent-company oversight.
Staar’s demand rebound in China is a direct read-through for global ophthalmic device demand expectations.
Counterpoint
Leadership appointments may not translate into revenue acceleration; for Masimo, the FDA clearance may be incremental unless adoption ramps quickly.
Key entities
- companyMasimo
Appointed Tim Benner as president under Danaher; cited FDA 510(k) clearance for a pediatric sedation score used in SedLine.
- companyStaar Surgical
Promoted Warren Foust to permanent CEO after the Alcon sale fell through; provided preliminary Q2 revenue outlook and set Aug. 12 full-results release.
- parent_companyDanaher
Named Julie Sawyer Montgomery CEO and president effective Oct. 1, overseeing Masimo acquisition integration.
- counterpartyAlcon
Proposed acquisition of Staar for $1.5B terminated after shareholder opposition.
